Active immunotherapy reduces <scp>NOTCH3</scp> deposition in brain capillaries in a <scp>CADASIL</scp> mouse model-Reference-Cited by-同舟云学术

Active immunotherapy reduces NOTCH3 deposition in brain capillaries in a CADASIL mouse model

Published:2022-12-16 Issue:2 Volume:15 Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Oliveira Daniel V¹²^ORCID,Coupland Kirsten G¹^ORCID,Shao Wenchao¹,Jin Shaobo¹³^ORCID,Del Gaudio Francesca³^ORCID,Wang Sailan¹,Fox Rhys¹³,Rutten Julie W⁴,Sandin Johan¹⁵⁶,Zetterberg Henrik⁷⁸⁹¹⁰¹¹,Lundkvist Johan¹⁵¹²,Lesnik Oberstein Saskia AJ⁴^ORCID,Lendahl Urban¹³^ORCID,Karlström Helena¹^ORCID

Affiliation:

1. Department of Neurobiology, Care Sciences and Society Karolinska Institutet Stockholm Sweden

2. Department of Cell Biology, Faculty of Science Charles University Prague Czech Republic

3. Department of Cell and Molecular Biology Karolinska Institutet Stockholm Sweden

4. Department of Clinical Genetics Leiden University Medical Center Leiden The Netherlands

5. Alzecure Foundation Huddinge Sweden

6. Alzecure Pharma Huddinge Sweden

7. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology The Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden

8. Clinical Neurochemistry Laboratory Sahlgrenska University Hospital Mölndal Sweden

9. Department of Neurodegenerative Disease UCL Institute of Neurology, Queen Square London UK

10. UK Dementia Research Institute at UCL London UK

11. Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay Hong Kong China

12. Sinfonia Biotherapeutics Huddinge Sweden

Funder

Gun och Bertil Stohnes Stiftelse

Hjärnfonden

Vetenskapsrådet

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.202216556

Reference48 articles.

1. A brief history of antibody-based therapy

2. Notch signaling: simplicity in design, versatility in function

3. Purification of mouse brain vessels;Boulay AC;J Vis Exp,2015

4. Clinical development of aducanumab, an anti‐Abeta human monoclonal antibody being investigated for the treatment of early Alzheimer's disease;Budd Haeberlein S;J Prev Alzheimers Dis,2017

5. Reducing Timp3 or vitronectin ameliorates disease manifestations in CADASIL mice

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mutant NOTCH3ECD Triggers Defects in Mitochondrial Function and Mitophagy in CADASIL Cell Models;Journal of Alzheimer's Disease;2024-08-13

2. Association of NOTCH3 Variant Risk Category With 2-Year Clinical and Radiologic Small Vessel Disease Progression in Patients With CADASIL;Neurology;2024-05-28

3. SNP and Structural Study of the Notch Superfamily Provides Insights and Novel Pharmacological Targets against the CADASIL Syndrome and Neurodegenerative Diseases;Genes;2024-04-23

4. Progress in the Study of the Role and Mechanism of HTRA1 in Diseases Related to Vascular Abnormalities;International Journal of General Medicine;2024-04

5. Protein aggregates containing wild-type and mutant NOTCH3 are major drivers of arterial pathology in CADASIL;Journal of Clinical Investigation;2024-02-22